Tausif Salim Highlights Key Insights Into Thrombosis Following TTVR
Tausif Salim, Principal Clinical Scientist at Abbott, shared a post on LinkedIn:
“I’ve been closely and enthusiastically following the topic of valve thrombosis — both clinical and subclinical — following transcatheter tricuspid valve replacement (TTVR). A recent meta-analysis article really highlights some critical considerations that device designers should take into account here.
– The tricuspid valve functions under low pressure and is located on the right side of the heart, where blood flow tends to be more stagnant compared to the left side. This reduced blood washout increases the risk of valve thrombosis.
– Some degree of valve thrombosis after TTVR seems inevitable. The key questions are: how significant is the issue, and what are the most effective strategies for managing it?
While thrombosis in the tricuspid position isn’t unexpected, there’s a clear opportunity to reduce its incidence through improved device design from the outset.
Moreover, we must consider the differences in clot formation kinetics and clot material properties between right and left sides of the heart. Hypoxia, which is known to promote thrombosis, adds another point for consideration.
From a scientific standpoint, this is particularly fascinating. Virchow’s triad — developed by Dr. Rudolph Virchow in 1856 to explain venous thrombosis and pulmonary embolism — identified three primary contributors to thrombus formation: venous stasis, endothelial injury, and blood hypercoagulability. The current findings in TTVR thrombosis seem to bring his foundational theory full circle. hashtag”
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic